Abstract 113P
Background
Our real-world data show high response rates with the COIB regimen for mCRC (Liu, Ou et al. 2022). But the appropriate dosage needs to be carefully explored. Therefore, we designed this prospective phase I/II study to determine the efficacy and tolerability of this combination regimen in the first-line treatment of mCRC.
Methods
This study consists of dose escalation (DES) and dose expansion (DEX). The primary objective in DES phase was to evaluate safety and tolerability of I combined with COB, followed by a DEX phase to verify the safety and tolerability profile of the combination therapy. Primary endpoints included recommended phase ll dose (RP2D) and efficacy of the combination. Other end points included exploratory biomarkers of drug activity. I was administered once a day (QD) at two dose levels (150mg/㎡ or 165mg/㎡) in combination with C (1g/㎡ bid, day 1-7)+ O (85mg/㎡, day 1)+B (5mg/kg, day 1), every 14 days (Q2W).
Results
As of August 13, 2023, 97 pts (median age: 58 years; 30% female; 77% left-sided intestine; 43 KRAS mutation, 6 NRAS mutation, 4 BRAF mutation, 31 wild type, 13 unknown) were treated (6 in DES, 91 in DEX). None of the 3 pts in irinotecan dose level 1 or 3 pts in irinotecan dose level 2 of DES had dose limiting toxicities (DLTs), and irinotecan (165mg/㎡, day1) was the RP2D. Treatment-related adverse events (TRAEs) of any grade occurred in 87 (89.7%) pts. TRAEs of grade ≥ 3 were mainly myelosuppression (20 pts, 20.6%) and diarrhea (10 pts, 10.3%). There were no fatal TRAEs. Of 90 pts evaluable for response, Objective response rate (ORR) was 73.3% (95% CI: 64.1%, 82.4%), Disease control rate (DCR) was 98.8% (95% CI: 96.7%, 100.0%).22 patients were successfully transformed and underwent radical resection, No evidence of disease (NED) rate was 22.7% (95% CI: 14.4%, 31.0%). With median follow-up of 17.0 months, 46 pts had progressive disease, median progression free survival (PFS) was 13.0 months(95%CI: 10.8, 19.3), overall survival (OS) are not yet mature. Detection biomarkers of drug activity is in progress.
Conclusions
The RP2D of irinotecan in COIB regimen is 165 mg/m2. The efficacy of the regimen is promising with well tolerance.
Clinical trial identification
NCT04380103.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Development Project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences (CICAMS-MODP2022002).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract